[go: up one dir, main page]

WO2009111169A2 - Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire - Google Patents

Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire Download PDF

Info

Publication number
WO2009111169A2
WO2009111169A2 PCT/US2009/034466 US2009034466W WO2009111169A2 WO 2009111169 A2 WO2009111169 A2 WO 2009111169A2 US 2009034466 W US2009034466 W US 2009034466W WO 2009111169 A2 WO2009111169 A2 WO 2009111169A2
Authority
WO
WIPO (PCT)
Prior art keywords
pkc
composition
inhibitor
leu
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/034466
Other languages
English (en)
Other versions
WO2009111169A3 (fr
Inventor
Keith Wayne Ward
Srini Venkatesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Publication of WO2009111169A2 publication Critical patent/WO2009111169A2/fr
Publication of WO2009111169A3 publication Critical patent/WO2009111169A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants

Definitions

  • the present invention relates to compositions and methods for effecting ocular neuroprotection.
  • the present invention relates to compositions that comprise modulators of protein kinase C- ⁇ ("PKC- ⁇ "), and to methods for effecting ocular neuroprotection using such compositions.
  • PKC- ⁇ protein kinase C- ⁇
  • the present invention relates to such compositions and methods for treating or controlling ocular neurodegenerative diseases.
  • glaucoma is an optic neuropathy with characteristic structural damage to the optic nerve, associated with progressive retinal ganglion cell death, loss of nerve fibers, and visual field loss.
  • Primary glaucoma is an independent syndrome in adults and may be classified as either chronic open-angle or chronic (acute) angle-closure.
  • Primary open-angle glaucoma is the most commonly occurring form of glaucoma, which appears to have no attributable underlying cause.
  • Angle-closure glaucoma usually afflicts those persons having "shallow" angles in the anterior chamber and results from the sides (or angles) of the chamber coming together and blocking aqueous outflow through the trabecular meshwork.
  • Secondary glaucoma results from pre-existing ocular diseases such as uveitis, intraocular tumor, or enlarged cataract.
  • glaucoma occurs in about 2 percent of all persons over the age of 40 and may be asymptomatic for years before progressing to rapid loss of vision.
  • the underlying causes of primary glaucoma are not yet well known.
  • An intraocular pressure (“lOP") that is high compared to the population mean is a risk factor for the development of glaucoma.
  • IOP intraocular pressure
  • many individuals with high IOP do not have glaucomatous loss of vision.
  • IOP intraocular pressure
  • there are glaucoma patients with normal IOP Therefore, continued efforts have been devoted to elucidate the pathogenic mechanisms of glaucomatous optic nerve degeneration.
  • optic nerve fibers are compressed by high IOP, leading to an effective physiological axotomy and problems with axonal transport.
  • High IOP also results in compression of blood vessels supplying the optic nerve heads ("ONHs"), leading to the progressive death of retinal ganglion cells (“RGCs”).
  • ONHs optic nerve heads
  • RRCs retinal ganglion cells
  • TNF- ⁇ tumor necrosis factor- ⁇
  • TNF- ⁇ and TNF- ⁇ receptor-1 are up-regulated in experimental rat models of glaucoma.
  • TNF- ⁇ -mediated RGC death involves the activation of both receptor-mediated caspase cascade and mitochondria- mediated caspase-dependent and caspase-independent components of cell death cascade.
  • G. Tezel and X. Yang Expt'l Eye Res., Vol. 81, 207 (2005).
  • TNF- ⁇ and its receptor were found in greater amounts in retina sections of glaucomatous eyes than in control eyes of age-matched normal donors.
  • G. Tezel et al. Invest. Ophthalmol. & Vis. ScL, Vol. 42, No. 8, 1787 (2001).
  • glaucomatous visual field loss is a clinically recognized condition. There has been compelling evidence that such vision loss results from damage to cells of the optic nerve system.
  • Retinitis pigmentosa another back-of-the-eye disease, is the term for a group of inherited diseases that affect the retina, the delicate nerve tissue composed of several cell layers that line the inside of the back of the eye and contain photoreceptor cells. These diseases are characterized by a gradual breakdown and degeneration of the photoreceptor cells (the rod and cone cells), which result in a progressive loss of vision. Retinitis pigmentosa affects thousands of individuals in the United States. Together, rods and cones are the cells responsible for converting light into electrical impulses that transfer messages to the retinal ganglion cells which in turn transmit the impulses through the lateral geniculate nucleus into that area of the brain where sight is perceived.
  • Retinitis pigmentosa therefore, affects a different retinal cell type than those affected by glaucoma.
  • the symptoms vary, and include night blindness, loss of peripheral vision (also referred to as tunnel vision), and loss of the ability to discriminate color before peripheral vision is diminished.
  • Symptoms of retinitis pigmentosa are most often recognized in adolescents and young adults, with progression of the disease usually continuing throughout the patient's life. The rate of progression and degree of visual loss are variable. As yet, there is no known cure for retinitis pigmentosa.
  • Age-related macular degeneration is a degenerative condition of the macula or central retina. It is the most common cause of vision loss in the over-50 age group. It is estimated that 50 million people worldwide suffer from AMD. Its prevalence increases with age and affects 15 percent of the population by age 55 and over 30 percent are affected by age 75. Macular degeneration can cause loss of central vision and make reading or driving impossible, but unlike glaucoma, macular degeneration does not cause complete blindness since peripheral vision is not affected. Macular degeneration can be detected during ophthalmologic examination.
  • Macular degeneration is classified as either dry (non-neovascular) or wet (neovascular). In its exudative or “wet” form, a layer of the retina becomes elevated with fluid, causing retinal detachment and wavy vision distortions. It has recently been discovered that mutations in two genes encoding proteins in the complement cascade, which is a part of the body's overall immune system, account for most of the risk of developing AMD. This complex molecular pathway is the body's first line of defense against invading bacteria, but if overactive, the pathway can produce tissue-damaging inflammation, which underlies the vision-destroying changes that particularly strike the macula.
  • drusen Proteins associated with immune system activity have been found in or near drusen, which are yellow deposits, in eyes with the dry form of AMD. Over time, the drusen grow as they accumulate inflammatory proteins and other materials, and the inflammation persists, causing additional damage to the retina and eventual vision loss. See; e.g., Science, Vol.311, 1704 (2006).
  • Diabetic retinopathy (DR)
  • DR Diabetic retinopathy
  • the clinical hallmarks of DR include increased vascular permeability, leading to macular edema, and endothelial cell proliferation. It has become apparent that degenerative changes occur beyond the vascular cells of the retina. These include increased retinal cell apoptosis, loss of ganglion cell bodies, reduced thickness of the inner retina, increased glial cell reactivity, microglia activation, and altered glutamate metabolism. Together, these changes lead to continuing degeneration of the retina and irreversible deficits in vision. AJ. Barber, Prog. Neuro-Psychopharmacol. & Biol. Psychiatry, Vol.
  • diabetes has an additive effect on neural apoptosis induced by increased lOP.
  • diabetes is a risk factor of glaucomatous optic neuropathy by making retinal glias and neurons, including RGCs, susceptible to the additional stress of high lOP.
  • ⁇ 2 -adrenergic receptor agonists have been noted to have neuroprotective effect on RGCs. See; e.g., E. Wolde-Mussie et al., invest. Ophthalmol. & Vis. ScI, Vol. 42, No. 12, 2849 (2001); M. P. Lafuente Lopez-Herrera et al., Expt'l Neurol., Vol. 178, 243 (2002). It has been reported that injected brimonidine and clonidine, which are among the ⁇ 2 -adrenergic receptor agonists, delay the secondary degeneration of axons after a partial optic nerve crush in rats, and the neuroprotective effect could be blocked by ⁇ 2 -antagonists. A.T.E. Hartwick, Optometry and Vision Science, Vol. 78, No. 2, 85 (2001) (noting E. Yoles et al., Ophthalmol. Vis. Sc/., Vol. 40, 65 (1999))-
  • the present invention provides compounds, compositions, and methods for providing neuroprotection to cells or components of a nervous system.
  • a nervous system comprises the human optic nerve system.
  • the present invention provides compounds, compositions, and methods for treating or controlling degeneration of at least a component of the human optic nerve system.
  • such degeneration comprises a pathological result of DR, AMD (including dry and wet AMD), retinitis pigmentosa, glaucoma, or combinations thereof.
  • composition of the present invention comprises a modulator of PKC- ⁇ , in an effective amount for treating or controlling degeneration of at least a component of the human optic nerve system.
  • composition of the present invention comprises a compound that substantially inhibits, reduces, or interferes with, an activity of a cell signaling cascade involving PKC- ⁇ , in an effective amount for treating or controlling degeneration of at least a component of the human optic nerve system.
  • a composition of the present invention comprises an inhibitor of, or an antagonist to, PKC- ⁇ , or an inhibitor of activation of PKC- ⁇ , in an amount effective for treating or controlling degeneration of at least a component of a human optic nerve system in a subject.
  • such PKC- ⁇ is a human PKC- ⁇ .
  • such PKC- ⁇ is expressed in a cell or tissue associated with the human optic nerve system. In yet another aspect, such PKC- ⁇ is activated in a cell or tissue associated with the human optic nerve system.
  • such a cell or tissue is associated with the retina or the optic nerve fiber.
  • such a PKC- ⁇ inhibitor is capable of down regulating a cell signaling pathway involving PKC- ⁇ .
  • composition of the present invention comprises a compound that is capable of inhibiting an activation of a human PKC- ⁇ signaling pathway.
  • composition of the present invention comprises: (a) a PKC- ⁇ inhibitor; and (b) an anti-inflammatory medicament.
  • the present invention provides a method for treating or controlling degeneration of at least a component of an optic nerve system.
  • the method comprises administering a composition to an affected eye, which composition comprises a PKC- ⁇ inhibitor; or a compound that is capable of inhibiting an activation of a human PKC- ⁇ signaling pathway; or a combination thereof; in an effective amount for treating or controlling such degeneration.
  • control also includes reduction, alleviation, amelioration, and prevention.
  • neuroprotection means the rescue of at least some cells or components of a nervous system that are not directly damaged by the primary cause of a disease or injury, but would otherwise undergo secondary degeneration without therapeutic intervention.
  • neuroprotection can lead to preservation of the physiological function of these cells or components.
  • a nervous system is the optic nerve system.
  • the cells or components of the optic nerve system include those being involved or assisting in conversion of photon to neurological signal and the transmission thereof from the retina to the brain for processing.
  • the main cells or components of the optic nerve system include, but are not limited to, pigment epithelial cells, photoreceptor cells (rod and cone cells), bipolar cells, horizontal cells, amacrine cells, interplexiform cells, ganglion cells, support cells to ganglion cells, and optic nerve fibers.
  • the present invention provides compounds, compositions, and methods for providing neuroprotection to cells or components of a nervous system.
  • a nervous system comprises the human optic nerve system.
  • the present invention provides compounds, compositions, and methods for treating or controlling degeneration of at least a component of the human optic nerve system.
  • a pharmaceutical composition of the present invention comprises an inhibitor of an activity of, or an antagonist to, PKC- ⁇ , or an inhibitor of activation of PKC- ⁇ , in an amount effective for providing neuroprotection to cells or components of a nervous system.
  • a pharmaceutical composition of the present invention comprises a PKC- ⁇ inhibitor in an amount effective for treating or controlling an ocular neurodegenerative condition in a subject.
  • such an ocular neurodegenerative condition comprises degeneration of a component of the human optic nerve system.
  • PKC- ⁇ inhibitor also includes compounds that inhibit or impede the expression or activation of PKC- ⁇ .
  • PKC- ⁇ inhibitor inhibits or is present in the composition at concentrations such that the composition is capable of treating or controlling neurodegeneration in a subject.
  • such PKC- ⁇ is human PKC- ⁇ .
  • such a PKC- ⁇ inhibitor is capable of down regulating a cell signaling pathway involving PKC- ⁇ .
  • such PKC- ⁇ is over-expressed in a cell or tissue associated with the human optic nerve system.
  • such PKC- ⁇ is over-activated in a cell or tissue associated with the human optic nerve system.
  • Such degeneration usually begins with disregulation of one or more biological compounds that are key to the maintenance of homeostasis.
  • the protein kinase C (“PKC”) family comprises twelve closely related isoforms of serine/threonine kinases.
  • the PKC family is subdivided into three major groups.
  • the conventional PKCs include the ⁇ , ⁇ l, ⁇ ll, and v isoforms and are activated by Ca 2+ and diacylglycerol ("DAG"), a level of which can increase because of hyperglycemia or diabetic state.
  • DAG diacylglycerol
  • the novel PKCs include the ⁇ , €, ⁇ , and ⁇ isoforms and are activated by DAG, but not Ca 2+ .
  • the atypical PKCs include the ⁇ and ⁇ /i isoforms, which are insensitive to both Ca 2+ and DAG.
  • PKC isoenzymes play a pivotal role as cellular mediators of signal transduction for hormones and growth factors as well as regulating diverse processes, including vascular haemodynamics, cellular proliferation and migration, neovascularization, enzyme activities, and gene expression of both growth factors and proto- oncogenes.
  • amounts of PKC proteins are found in most types of tissues at regulated levels for normal body function.
  • some PKC isozymes show distinctive distribution in different tissues. For example, PKC- ⁇ l and - ⁇ ll are present in greatest amount in the brain and spleen. PKC- ⁇ is seen mostly in the brain, and to a lesser degree, in the adrenal tissue.
  • PKC- ⁇ is concentrated in the brain, heart, spleen, lung, liver, ovary, pancreas, and adrenal tissues. PKC- ⁇ is present in the brain, kidney, and pancreas. PKC- ⁇ is found mostly in the brain, lung, and liver. PKC- ⁇ is present predominantly in T lymphocytes and muscle cells. In particular, PKC- ⁇ is only one of three PKCs (along with PKC- ⁇ and PKC- ⁇ ll) found in retinal pigment epithelial (“RPE”) cells, pericytes, and endothelial cells of the retina.
  • RPE retinal pigment epithelial
  • PKC- ⁇ also promotes neutrophils degranulation, facilitating the release of proteases that can damage the brain tissues.
  • the present inventors recognize that such results can occur similarly in optic nerve tissues following retinal ischemia resulting from a prolonged diabetic state.
  • PKC- ⁇ becomes activated during glutamate-induced oxidative stress. Prolonged glutamate-induced activation of PKC- ⁇ leads to reduced activity of mitogen-activated kinase phosphatase-1 ("MKP-1"), which regulates cell survival, differentiation, and apoptosis, and eventually neuronal cell death.
  • MKP-1 mitogen-activated kinase phosphatase-1
  • Glutamate is the principal excitory neurotransmitter in the CNS, including retinal ganglion cells, and is normally released from presynaptic terminals of neurons in controlled small amounts.
  • glutamate After binding to glutamate receptors, glutamate is taken up by excitory amino-acid transporters mainly into glia where it is metabolized to glutamine. This uptake is the primary mechanism for extracellular glutamate clearance to protect the CNS from glutamate excitotoxicity.
  • excessive or prolonged glutamate release following extended exposure to stimuli or stress and/or impairment of glutamate uptake and the resulting excessive stimulation of glutamate receptors have been implicated in neuronal death associated with a wide range of neurodegenerative diseases, such as Parkinson's disease, Huntington's disease, and Alzheimer's disease. B-H Choi et al., supra. Glutamate is released in large amounts by neurons following ischemic insults. Chronic elevation of glutamate level was shown to be toxic to retinal ganglion cells. CK. Vorwerk et al., Invest. Ophthalmol. Vis. Sd., Vol. 37, No. 8, 1618 (1996).
  • the level of glutamate in retina of diabetic rats was found to increase by 40 folds.
  • glutamate was found to accumulate in the vitreous of diabetic patients with proliferative diabetic retinopathy. J. Ambati et al., Arch. Ophthalmol., Vol. 115, 1161 (1997).
  • an acute partial lesion of the optic nerve in a rat model as a simulated condition of glaucomatous injury led to intraocular elevation of glutamate by 54%, three days, and 79%, seven days after the onset of the injury.
  • the present invention provides compositions and methods for treating or controlling an ocular neurodegenerative condition in a subject.
  • compositions provide ocular neuroprotection in the subject through inhibiting or antagonizing activity of human PKC- ⁇ .
  • a composition of the present invention comprises a modulator of PKC- ⁇ , in an effective amount for treating or controlling degeneration of at least a component of the human optic nerve system.
  • a composition of the present invention comprises a compound that substantially inhibits, reduces, or interferes with, an activity of a cell signaling cascade involving PKC- ⁇ , in an effective amount for treating or controlling degeneration of at least a component of the human optic nerve system.
  • composition of the present invention comprises a compound that substantially inhibits, reduces, or interferes with, activation of PKC- ⁇ , in an effective amount for treating or controlling degeneration of at least a component of the human optic nerve system.
  • composition of the present invention comprises a PKC- ⁇ inhibitor and an anti-inflammatory medicament.
  • an anti-inflammatory medicament comprises a nonsteroidal compound.
  • PKC- ⁇ protein comprises a regulatory domain and a catalytic domain.
  • the regulatory domain (including amino acids 1-280) comprises a subdomain Cl homologous to other members of the PKC family and three variable subdomains V1, V2, and V3.
  • the catalytic domain (including amino acids 349-675) comprises homologous subdomains C3 and C4 and variable domains V4 and V5.
  • a PKC- ⁇ inhibitor comprises an agent which decreases the level of PKC- ⁇ expression and/or activity.
  • An agent that decreases the level of PKC- ⁇ expression or activity can be one or more of: a PKC- ⁇ antagonist (e.g., a PKC- ⁇ binding protein that binds to PKC- ⁇ but does not activate the enzyme); a PKC- ⁇ nucleic acid molecule that can bind to a cellular PKC- ⁇ nucleic acid sequence (e.g., mRNA) and inhibit expression of the protein (e.g., an antisense molecule or PKC- ⁇ ribozyme); an antibody that specifically binds to PKC- ⁇ protein (e.g., an antibody that disrupts PKC- ⁇ 's catalytic activity or an antibody that disrupts the ability of upstream activators to activate PKC- ⁇ ); an agent that decreases PKC- ⁇ gene expression and/or activity (e.g., a small molecule that inhibits PKC- ⁇ (e.g., Rottlerin
  • PKC- ⁇ expression is inhibited by decreasing the level of expression of an endogenous PKC- ⁇ gene (e.g., by decreasing transcription of the PKC- ⁇ gene).
  • transcription of the PKC- ⁇ gene can be decreased by: altering the regulatory sequences of the endogenous PKC- ⁇ gene (e.g., by the addition of a negative regulatory sequence, such as a DNA-biding site for a transcriptional repressor, or by the removal of a positive regulatory sequence, such as an enhancer or a DNA-binding site for a transcriptional activator).
  • a PKC- ⁇ inhibitor included in a composition of the present invention comprise rottlerin (also known as mallotoxin or i-[6-[(3-acetyl- 2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyI-2H-i- benzopyran-8-yl]-3-phenyl-2-propen-i-one, available from Calbiochem, San Diego, California) having Formula I, or a derivative or analogue thereof.
  • rottlerin also known as mallotoxin or i-[6-[(3-acetyl- 2,4,6-trihydroxy-5-methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyI-2H-i- benzopyran-8-yl]-3-phenyl-2-propen-i-one, available from Calbiochem, San Diego, California
  • a PKC- ⁇ inhibitor included in a composition of the present invention comprises an antibody specifically reactive with human PKC- ⁇ or a fragment of such antibody.
  • Anti-protein/anti-peptide antisera or monoclonal antibodies can be made by using standard protocols (See; e.g., "Antibodies: A Laboratory Manual” ed. by Harlow and Lane (Cold Spring Harbor Press, 1988)).
  • PKC- ⁇ or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind the component using standard techniques for polyclonal and monoclonal antibody preparation.
  • the full-length protein can be used or, alternatively, antigenic peptide fragments of the protein can be used as immunogens.
  • a peptide is used to prepare antibodies by immunizing a suitable subject (e.g., rabbit, goat, mouse or other mammal) with the immunogen.
  • An appropriate immunogenic preparation can contain, for example, a recombinant or a chemically synthesized PKC peptide. See, e.g., US Patents 5 * 460,959; 5,994,127; 6,048,729; and 6,063,630; which are hereby expressly incorporated by reference in their entirety.
  • the nucleotide and amino acid sequence of human PKC- ⁇ is shown below (SEQ. NO.1).
  • the preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic PKC- ⁇ preparation induces a polyclonal anti-PKC antibody response.
  • Fragments of antibodies to PKC- ⁇ can be generated by treating the antibody with an enzyme such as pepsin.
  • the term "monoclonal antibody” or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope. A monoclonal antibody composition thus typically displays a single binding affinity for a particular protein with which it immunoreacts.
  • antibodies produced by genetic engineering methods such as chimeric or humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, can be used.
  • Such chimeric or humanized monoclonal antibodies can be produced by genetic engineering using standard DNA techniques known in the art, for example using methods described in US Patents 5,721, 108; 5,677,180 and 5,50,362 (Robinson et al.); US Patent 4,935,496 (Akira et a!.); US Patent 5,807,715 (Morrison et al.); US Patent 4,816,567 (Cabilly et al.); which are incorporated herein by reference in their entirety; A. Y.
  • a monoclonal antibody directed against human PKC- ⁇ described herein can be made using standard techniques.
  • monoclonal antibodies can be generated in transgenic mice or in immune deficient mice engrafted with antibody-producing human cells. Methods of generating such mice are describe, for example, in S.L Morrison et al., PNAS, Vol. 81, No. 21, 6851 (1984); N. Tuaillon et al., PNAS, Vol.
  • Monoclonal antibodies against human PKC- ⁇ isoform disclosed herein can also be prepared by constructing a combinatorial immunoglobulin library, such as a Fab phage display library or a scFv phage display library, using immunoglobulin light chain and heavy chain cDNAs prepared from mRNA derived from lymphocytes of a subject. See, e.g., US Patent 5,969,108 (McCafferty et al.), which is incorporated herein by reference in its entirety, and A. D. Griffths et al., EMBOJ, Vol. 12, No. 2, 725 (1993).
  • a combinatorial library of antibody variable regions can be generated by mutating a known human antibody.
  • variable region of a human antibody known to bind PKC- ⁇ can be mutated by, for example, using randomly altered mutagenized oligonucleotides, to generate a library of mutated variable regions which can then be screened to bind to PKC- ⁇ .
  • Methods of inducing random mutagenesis within the CDR regions of immunoglobin heavy and/or light chains, methods of crossing randomized heavy and light chains to form pairings and screening methods can be found in, for example, US Patent 5,667,988 (Barbas III et al.), which is incorporated herein by reference in its entirety, and CF. Barbas III et al., PNAS, Vol. 89, No. 10, 4457
  • the immunoglobulin library can be expressed by a population of display packages, preferably derived from filamentous phage, to form an antibody display library.
  • Non-limiting examples of methods and reagents particularly amenable for use in generating antibody display library can be found in, for example, US Patent 5,223,409 (Ladner et al.); US Patent 5,759,817 (Kang et al.); and US Patent 5,969,108 (McCafferty et al.); which are incorporated herein by reference in their entirety; A.D. Griffths et al. (1993) supra; H. Gram et al., PNAS, Vol. 89, No. 8, 3576 (1992); and CF.
  • the antibody library is screened to identify and isolate packages that express an antibody that binds PKC- ⁇ described herein.
  • the primary screening of the library involves panning with an immobilized PKC- ⁇ described herein and display packages expressing antibodies that bind the immobilized PKC- ⁇ are selected.
  • antiobodies to human PKC- ⁇ may be obtained from Santa Cruz Biotechnology, Inc., Santa Cruz, California; Calbiochem, San Diego, California; or Abeam Inc., Cambridge, Massachusetts (e.g. SEQ. NO. 7-8).
  • a PKC- ⁇ inhibitor included in a composition of the present invention comprises a short peptide PKC- ⁇ antagonist having a sequence selected from the group consisting of SEQ. NO. 9-42.
  • These short peptides can be recombinantly produced or chemically synthesized.
  • the peptides having SEQ. NO. 9-42 and other suitable related short peptides are disclosed in US Patent 6,855,693; which is incorporated herein by reference in its entirety.
  • Nucleic acid molecules that are "antisense” to a nucleotide sequence encoding human PKC- ⁇ can be used as an agent that inhibits expression of human PKC- ⁇ .
  • An "antisense" nucleic acid includes a nucleotide sequence that is complementary to a "sense” nucleic acid encoding the protein, e.g., complementary to the coding strand of a double- stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can form hydrogen bonds with a sense nucleic acid.
  • the antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof. For example, an antisense nucleic acid molecule that is complementary to the "coding region" of the coding strand of a nucleotide sequence encoding the protein can be used.
  • An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length.
  • An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.
  • an antisense nucleic acid e.g., an antisense oligonucleotide
  • an antisense nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.
  • modified nucleotides which can be used to generate the antisense nucleic acid include 5-fIuorouracil, 5-bromouraciI, 5-chlorouraciI, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxyImethyl) uracil, 5- carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1- methylguanine, i-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2- methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7- methylguanine, 5-methylaminomethyluraciI, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5-methyl
  • the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest.
  • an antisense orientation i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest.
  • a PKC- ⁇ inhibitor included in a composition of the present invention comprises a small nucleic acid molecule that downregulates, inhibits, or reduces the expression of PKC- ⁇ , or the expression or activity of another gene involved in a pathway of PKC- ⁇ gene expression.
  • nucleic acid molecules include short interfering nucleic acid (“siNA”), short interfering RNA (“siRNA”), double stranded RNA (“dsRNA”), micro-RNA (“miRNA”), and short hairpin RNA (“shRNA”).
  • nucleic acid molecules are disclosed, for example, in US Patents 5,514,567; 5,561,222; 6,506,559; 7,022,828; 7,078,196; 7,176,304; 7,282,564; and 7,294,504; which are incorporated herein by reference in their entirety.
  • interfering RNA can be readily designed when the nucleic acid sequence for the target is known.
  • useful PKC- ⁇ siRNAs may be those available from Addgene, Inc., Cambridge, Massachusetts, or from Qiagen, Inc., Valencia, California.
  • a PKC- ⁇ inhibitor that may be included in compositions of the present invention comprises a plasmid comprising a nucleic acid sequence, such as those selected from the group consisting of SEQ. NO. 3-4, ligated to a vector, such as pSUPER, for expressing siRNA.
  • pSUPER vector is available from OligoEngine, Seattle, Washington. See also T. R. Brummelkamp et al., Cancer Cell, Vol. 2, 243 (2002).
  • the vector can be an adenovirus vector, available from, for example, Quantum Biotechnologies, Inc., Laval, Quebec, Canada.
  • an RNA-interferring PKC- ⁇ inhibitor can be a naked nucleic acid having SEQ. NO. 5-6. N. lrie et al., Biochem Biophys. Res. Comm., Vo. 298, 738 (2002).
  • a PKC- ⁇ inhibitor is included in a composition of the present invention in an amount from about 0.0001 to about 10 percent by weight of the composition.
  • such PKC- ⁇ inhibitor is present in a composition of the present invention in an amount from about 0.001 to about 5 percent (or from about 0.001 to about 2, or from about 0.001 to about 1, or from about 0.001 to about 0.5, or from about 0.001 to about 0.2, or from about 0.001 to about 0.1, or from about 0.01 to about 0.1, or from about 0.01 to about 0.5, or from about 0.01 to about 1, or from about 0.001 to about 0.01, or from about 0.001 to about 0.1 percent, or from about 0.1 to about 5, or from about 0.1 to about 2, or from about 0.1 to about 1, or from about 0.1 to about 0.5, or from about 0.1 to about 0.2) by weight of the composition.
  • a composition of the present invention comprises: (a) a PKC- ⁇ inhibitor; and (b) an anti-
  • such an anti-inflammatory agent is selected from the group consisting of non-steroidal anti-inflammatory drugs ("NSAIDs”), peroxisome proliferator-activated receptor (“PPAR”) ligands, combinations thereof, and mixtures thereof.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • PPAR peroxisome proliferator-activated receptor
  • Non-limiting examples of the NSAIDs are: aminoarylcarboxylic acid derivatives (e.g., enfenamic acid, etofenamate, flufenamic acid, isonixin, meclofenamic acid, mefenamic acid, niflumic acid, talniflumate, terofenamate, tolfenamic acid), arylacetic acid derivatives (e.g., aceclofenac, acemetacin, alclofenac, amfenac, amtolmetin guacil, bromfenac, bufexamac, cinmetacin, clopirac, diclofenac sodium, etodolac, felbinac, fenclozic acid, fentiazac, glucametacin, ibufenac, indomethacin, isofezolac, isoxepac, lonazolac, metiazinic acid, mof
  • an anti-inflammatory agent is a PPAR-binding molecule.
  • a PPAR-binding molecule is a PPARa-, PPAR5-, or PPAR ⁇ -binding molecule.
  • a PPAR-binding molecule is a PPAR ⁇ , PPAR ⁇ , or PPARy agonist.
  • Such a PPAR ligand binds to and activates PPAR to modulate the expression of genes containing the appropriate peroxisome proliferator response element in its promoter region.
  • PPARY agonists can inhibit the production of TNF- ⁇ and other inflammatory cytokines by human macrophages (C-Y. Jiang et al., Nature, Vol. 391, 82-86 (1998)) and T lymphocytes (A.E. Giorgini et al., Horm. Metab. Res. Vol. 31, 1-4 (1999)). More recently, the natural PPARY agonist i5-deoxy- ⁇ -i2,i4-prostaglandin J2 (or "i5-deoxy- ⁇ -i2,i4-PG J2”), has been shown to inhibit neovascularization and angiogenesis (X. Xin et al., J. Biol. Chem. Vol.
  • PPARY is expressed to different degrees in the various tissues of the eye, such as some layers of the retina and the cornea, the choriocapillaris, uveal tract, conjunctival epidermis, and intraocular muscles (see, e.g., U.S. Patent 6,316,465).
  • a PPARy agonist used in a composition or a method of the present invention is a thiazolidinedione, a derivative thereof, or an analog thereof.
  • thiazolidinedione-based PPARy agonists include pioglitazone, troglitazone, ciglitazone, englitazone, rosiglitazone, and chemical derivatives thereof.
  • PPARy agonists include Clofibrate (ethyl 2-(4- chlorophenoxy)-2-methylpropionate), clofibric acid (2-(4-chIorophenoxy)-2- methylpropanoic acid), GW 1929 (N-(2-benzoylphenyl)-O- ⁇ 2-(methyl-2- pyridinylamino)ethyl ⁇ -L-tyrosine), GW 7647 (2- ⁇ 4- ⁇ 2-
  • GW 1929, GW 7647, and WY 14643 are commercially available, for example, from Koma Biotechnology, Inc. (Seoul, Korea).
  • the PPARy agonist is i5-deoxy- ⁇ -i2, 14-PG J2.
  • Non-limiting examples of PPAR- ⁇ agonists include the fibrates, such as fenofibrate and gemfibrozil.
  • a non-limiting example of PPAR- ⁇ agonist is GW501516 (available from Axxora LLC, San Diego, California or EMD Biosciences, Inc., San Diego, California).
  • Each of said anti-inflammatory agents when included in a composition, is present in a composition of the present invention in an amount from about 0.001 to about 5 percent (or from about 0.001 to about 2, or from about 0.001 to about 1, or from about 0.001 to about 0.5, or from about 0.001 to about 0.2, or from about 0.001 to about 0.1, or from about 0.01 to about 0.1, or from about 0.01 to about 0.5, or from about 0.001 to about 0.01, or from about 0.001 to about 0.1 percent) by weight of the composition.
  • a composition of the present invention comprises a liquid medium.
  • the liquid medium comprises an aqueous solution.
  • the liquid medium comprises a non-aqueous formulation.
  • composition of the present invention further comprises a material selected from the group consisting of preservatives, antimicrobial agents, surfactants, buffers, tonicity-modifying agents, chelating agents, viscosity-modifying agents, co-solvents, oils, humectants, emollients, stabilizers, antioxidants and combinations thereof.
  • Water-soluble preservatives that may be employed in a composition of the present invention include benzalkonium chloride, benzoic acid, benzoyl chloride, benzyl alcohol, chlorobutanol, calcium ascorbate, ethyl alcohol, potassium sulfite, sodium ascorbate, sodium benzoate, sodium bisulfite, sodium bisulfate, sodium thiosulfate, thimerosal, methylparaben, ethylparaben, propylparaben, polyvinyl alcohol, phenylethyl alcohol, quaternary alkyl ammonium salts (such as Polyquaternium-1 or Polyquatemium-io), hydrogen peroxide, and urea peroxide, and biguanides.
  • benzalkonium chloride benzoic acid
  • benzoyl chloride benzyl alcohol
  • chlorobutanol calcium ascorbate
  • ethyl alcohol potassium sulfite
  • preservatives useful in the present invention include, but are not limited to, the FDA-approved preservative systems for food, cosmetics, and pharmaceutical preparations. These agents may be present in individual amounts of from about o.ooi to about 5 percent by weight (preferably, from about 0.01 percent to about 2 percent by weight; more preferably, from about 0.01 percent to about 1 percent by weight).
  • a composition of the present invention comprises an anti-microbial agent.
  • antimicrobial agents include the quaternary ammonium compounds and bisbiguanides.
  • Representative examples of quaternary ammonium compounds include benzalkonium halides and balanced mixtures of n-alkyl dimethyl benzyl ammonium chlorides.
  • antimicrobial agents include polymeric quaternary ammonium salts used in ophthalmic applications such as poIy[(dimethyliminio)-2-butene-i,4-diyI chloride], [4-tris(2-hydroxyethyI)ammonio]-2-butenyI-w-[tris(2- hydroxyethyl)ammonio]dichloride (chemical registry number 75345-27-6) generally available as Polyquatemiurn-i ® from ONYX Corporation.
  • polymeric quaternary ammonium salts used in ophthalmic applications such as poIy[(dimethyliminio)-2-butene-i,4-diyI chloride], [4-tris(2-hydroxyethyI)ammonio]-2-butenyI-w-[tris(2- hydroxyethyl)ammonio]dichloride (chemical registry number 75345-27-6) generally available as Polyquatemiurn-i ® from ONYX Corporation
  • Non-limiting examples of antimicrobial biguanides include the bis(biguanides), such as alexidine or chlorhexidine or salts thereof, and polymeric biguanides such as polymeric hexamethylene biguanides (“PHMB”) and their water-soluble salts, which are available, for example, from Zeneca, Wilmington, Delaware.
  • bis(biguanides) such as alexidine or chlorhexidine or salts thereof
  • polymeric biguanides such as polymeric hexamethylene biguanides (“PHMB”) and their water-soluble salts, which are available, for example, from Zeneca, Wilmington, Delaware.
  • PHMB polymeric hexamethylene biguanides
  • a composition of the present invention includes a disinfecting amount of an antimicrobial agent that will at least prevent the growth of microorganisms in the formulations employed.
  • a disinfecting amount is that which will reduce the microbial burden by two log orders in four hours and more preferably by one log order in one hour.
  • such agents are present in concentrations ranging from about 0.00001 to about 0.5 percent (w/v); preferably, from about 0.00003 to about 0.5 percent (w/v); and more preferably, from about 0.0003 to about 0.1 percent (w/v).
  • a composition of the present invention comprises a surfactant.
  • Suitable surfactants can be amphoteric, cationic, anionic, or non- ionic, which may be present (individually or in combination) in amounts up to 15 percent, preferably up to 5 percent weight by volume (w/v) of the total composition (solution).
  • the surfactant is an amphoteric or non-ionic surfactant, which when used imparts cleaning and conditioning properties.
  • the surfactant should be soluble in the lens care solution and non- irritating to eye tissues.
  • Many non-ionic surfactants comprise one or more chains or polymeric components having oxyalkylene (-O-R-) repeating units wherein R has 2 to 6 carbon atoms.
  • Preferred non-ionic surfactants comprise block polymers of two or more different kinds of oxyalkylene repeat units. Satisfactory non-ionic surfactants include polyethylene glycol esters of fatty acids, polysorbates, polyoxyethylene, or polyoxypropylene ethers of higher alkanes (C 12 -C 18 ).
  • Non-limiting examples of the preferred class include polysorbate 8o (polyoxyethylene sorbitan monooleate), polysorbate 6o (polyoxyethylene sorbitan monostearate), polysorbate 20 (polyoxyethylene sorbitan monolaurate), commonly known by their trade names of Tween® 8o, Tween® 6o, Tween® 20), poloxamers (synthetic block polymers of ethylene oxide and propylene oxide, such as those commonly known by their trade names of Pluronic®; e.g., Pluronic® F127 or Pluronic® F108) ), or poloxamines (synthetic block polymers of ethylene oxide and propylene oxide attached to ethylene diamine, such as those commonly known by their trade names of Tetronic®; e.g., Tetronic® 1508 or Tetronic® 908, etc., other nonionic surfactants such as Brij®, Myrj®, and long chain fatty alcohols (i.e., oleyl alcohol,
  • concentration of a non-ionic surfactant, when present, in a composition of the present invention can be in the range from about 0.001 to about 5 weight percent (or alternatively, from about 0.01 to about 4, or from about 0.01 to about 2, or from about 0.01 to about 1 weight percent).
  • Amphoteric surfactants suitable for use in a composition according to the present invention include materials of the type offered commercially under the trade name "Miranol.” Another useful class of amphoteric surfactants is exemplified by cocoamidopropyl betaine, commercially available from various sources.
  • the foregoing surfactants will generally be present in a total amount from 0.001 to 5 percent weight by volume (w/v), or 0.01 to 5 percent, or 0.01 to 2 percent, or 0.1 to 1.5 percent (w/v).
  • the pH of a composition of the present invention is maintained within the range of 5 to 8, preferably about 6 to 8, more preferably about 6.5 to 7.8.
  • suitable buffers include boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na 2 HPO 4 , NaH 2 PO 4 and KH 2 PO 4 ) and mixtures thereof.
  • Borate buffers are preferred, particularly for enhancing the efficacy of biguanides, when they are used in compositions of the present invention.
  • buffers will be used in amounts ranging from about 0.05 to 2.5 percent by weight, and preferably, from 0.1 to 1.5 percent.
  • the compositions comprise a borate or mixed phosphate buffer, containing one or more of boric acid, sodium borate, potassium tetraborate, potassium metaborate, or mixtures of the same.
  • chelating or sequestering agents in the present compositions in order to bind metal ions, which might otherwise react with the lens and/or protein deposits and collect on the lens.
  • Ethylene-diaminetetraacetic acid (“EDTA”) and its salts (disodium) are preferred examples. They are usually added in amounts ranging from about 0.01 to about 0.3 weight percent.
  • EDTA Ethylene-diaminetetraacetic acid
  • Other suitable sequestering agents include phosphonic acids, gluconic acid, citric acid, tartaric acid, and their salts; e.g., sodium salts.
  • compositions of the present invention comprise a tonicity-adjusting agent, to approximate the osmotic pressure of normal lacrimal fluid, which is equivalent to a 0.9 percent solution of sodium chloride or 2.5 percent of glycerol solution.
  • suitable tonicity-adjusting agents include, but are not limited to, sodium and potassium chloride, calcium and magnesium chloride, dextrose, glycerin, mannitol, and sorbitol. These agents are typically used individually in amounts ranging from about 0.01 to 2.5 percent (w/v) and preferably, form about 0.2 to about 1.5 percent (w/v).
  • the tonicity-adjusting agent will be employed in an amount to provide a final osmotic value of 200 to 450 m ⁇ sm/kg; more preferably, between about 250 to about 350 m ⁇ sm/kg, and most preferably between about 280 to about 320 mOsm/Kg.
  • viscosity-modifying agents Because of their demulcent effect, viscosity-modifying agents have a tendency to enhance the patient's comfort by means of a lubricating film on the eye.
  • the water-soluble viscosity-modifying agents include the cellulose polymers like hydroxyethyl or hydroxypropyl cellulose, carboxymethyl cellulose and the like. Such viscosity-modifying agents may be employed in amounts ranging from about 0.01 to about 4 weight percent or less.
  • the present compositions may also include optional demulcents.
  • composition of the present invention can include additives such as co-solvents, oils, humectants, emollients, stabilizers, or antioxidants for a variety of purposes. These additives may be present in amounts sufficient to provide the desired effects, without impacting the performance of other ingredients.
  • a PKC- ⁇ inhibitor comprises a nucleic acid molecule
  • such molecule can be administered into a subject using in vivo gene therapy techniques (such as those disclosed in U.S. Pat. No. 5,399,346; which is incorporated herein by reference in its entirety).
  • the nucleic-acid PKC- ⁇ inhibitor incorporated into cells (e.g., ocular cells) of the host suppresses the in vivo activity of PKC- ⁇ and produces neuroprotection to the subject.
  • the cells can be in the subject and the nucleic acid can be administered in a pharmaceutically acceptable carrier.
  • the subject can be any animal in which it is desirable to selectively express a nucleic acid in a cell.
  • the animal of the present invention is a human.
  • non-human animals which can be treated by a method of this invention can include, but are not limited to, non-human primates, cats, dogs, birds, horses, cows, goats, sheep, guinea pigs, hamsters, gerbils and rabbits, as well as any other animal in which selective expression of a nucleic acid in a cell can be carried out according to the methods described herein.
  • a nucleic acid of the present invention can be in the form of naked DNA or RNA or the nucleic acids can be in a vector for delivering the nucleic acid to the cells for expression of the nucleic acid inside the cell.
  • the vector can be a commercially available preparation, such as those disclosed herein above. Delivery of the nucleic acid or vector to cells can be via a variety of mechanisms.
  • delivery can be via a liposome, using commercially available liposome preparations such as Lipofectin ® , Lipofectamine ® (GIBCO-BRL, Inc., Gaithersburg, Maryland), Superfect ® (Qiagen Inc., Valencia, California) and Transfectam ® (Promega Biotec, Inc., Madison, Wisconsin), as well as other liposomes developed according to procedures standard in the art.
  • the nucleic acid or vector of this invention can be delivered in vivo by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, California) as well as by means of a sonoporation machine (ImaRx Pharmaceutical Corp., Arlington, Arizona).
  • vector delivery can be via a viral system, such as a retroviral vector system which can package a recombinant retroviral genome.
  • the recombinant retrovirus can then be used to infect and thereby deliver nucleic acid to the infected cells.
  • the exact method of introducing the nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors.
  • Other techniques are widely available for this procedure including the use of adenoviral vectors, adeno-associated viral ("AAV") vectors, lentiviral vectors, pseudotyped retroviral vectors, and pox virus vectors, such as vaccinia virus vectors.
  • Physical transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis mechanism.
  • a method disclosed herein can be used in conjunction with any of these or other commonly used gene transfer methods.
  • the nucleic acid and the nucleic acid delivery vehicles of this invention can be in a pharmaceutically acceptable carrier for in vivo administration to a subject.
  • pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vehicle, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
  • the carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
  • the nucleic acid or vehicle may be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, transdermal ⁇ , extracorporeal ⁇ , topically or the like.
  • parenterally e.g., intravenously
  • intramuscular injection by intraperitoneal injection, transdermal ⁇ , extracorporeal ⁇ , topically or the like.
  • the exact amount of the nucleic acid or vector required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity or mechanism of any disorder being treated, the particular nucleic acid or vehicle used, its mode of administration and the like.
  • the compounds of this invention can be administered to a cell of a subject either in vivo or ex vivo.
  • the compounds of this invention can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, subcutaneous injection, transdermally, extracorporeal ⁇ , topically, mucosally or the like.
  • the compounds of the present invention can be in pharmaceutical compositions in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, pills, capsules, powders, liquids, suspensions, lotions, creams, gels, or the like.
  • the compositions will include, as noted above, an effective amount of the selected compound, possibly in combination with a pharmaceutically acceptable carrier and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc., many of which are disclosed herein.
  • Parenteral administration of the compounds of the present invention is generally characterized by injection.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions.
  • parenteral administration includes intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous and intratracheal routes. Parenteral administration can involve use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., US Patent 3,610,795, which is incorporated by reference herein.
  • These compounds can be present in a pharmaceutically acceptable carrier, which can also include a suitable adjuvant.
  • the exact amount of the compound required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the particular compound used, its mode of administration and the like. An appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.
  • cells or tissues can be removed and maintained outside the subject's body according to standard protocols well known in the art.
  • the compounds of this invention can be introduced into the cells via known mechanisms for uptake of small molecules into cells (e.g., phagocytosis, pulsing onto class I MHC-expressing cells, liposomes, etc.).
  • the compounds of this invention can also be linked to the homeodomain of Antennapedia for introduction, i.e. internalization of the compound, into cells (P. Prochiantz, Curr. Opin. Neurobiol., Vol. 6, No. 5, 629 (1996)).
  • the cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or transplanted back into the subject per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a subject.
  • compositions of the present invention serve to illustrate some non-limiting compositions of the present invention.
  • the ingredients shown in each of Tables 1-10 are mixed to form a pharmaceutical composition for treating or controlling ocular neurodegenerative conditions.
  • the composition may be further sterilized prior to administration to the subject, according to known methods of sterilization of pharmaceutical compositions.
  • a preservative other than polyhexamethylenebiguanide HCl may be used in any one of the foregoing formulation, in a suitably effective amount.
  • a composition can be free of preservative if it is formulated to be used as a unit-dose composition.
  • the composition is packaged in an individual container that is opened and the contents of the container are used only once.
  • the present invention also provides a method for treating or controlling degeneration of at least a component of the optic nerve system.
  • the method comprises applying a composition to the eye, wherein the composition comprises compound that substantially inhibits, reduces, or interferes with, an activity of a cell signaling cascade involving PKC- ⁇ , antagonizes PKC- ⁇ , or inhibits the activation of PKC- ⁇ , or a combination thereof, in an effective amount for treating or controlling such degeneration.
  • one or more PKC- ⁇ inhibitors is incorporated into a formulation for topical administration, systemic administration, periocular injection, or intravitreal injection.
  • a formulation can desirably comprise a carrier that provides a sustained release of the active ingredients, such as for a period longer than about 1 week (or longer than about 1, 2, 3, 4, 5, or 6 months).
  • the sustained-release formulation desirably comprises a carrier that is insoluble or only sparingly soluble in the ocular environment.
  • a carrier can be an oil-based liquid, emulsion, gel, or semisolid.
  • oil-based liquids include castor oil, peanut oil, olive oil, coconut oil, sesame oil, cottonseed oil, corn oil, sunflower oil, fish-liver oil, arachis oil, and liquid paraffin.
  • a composition of the present invention can be injected intravitreally to control the progression of an ocular neurodegenerative disease, using a fine-gauge needle, such as 25-33 gauge.
  • a fine-gauge needle such as 25-33 gauge.
  • an amount from about 25 ⁇ l to about 100 ⁇ l of a composition comprising one or more PKC- ⁇ inhibitors is administered into a patient.
  • a concentration of such a PKC ⁇ inhibitor or combination thereof is selected from the ranges disclosed above.
  • one or more PKC- ⁇ inhibitors is incorporated into an ophthalmic device or system that comprises a biodegradable material, and the device is implanted into the posterior cavity of a diseased eye to provide a long- term (e.g., longer than about 1 week, or longer than about 1, 2, 3, 4, 5, or 6 months) control of progression of an ocular neurodegenerative disease.
  • a long- term e.g., longer than about 1 week, or longer than about 1, 2, 3, 4, 5, or 6 months
  • control is achieved by reducing the levels of pro-inflammatory cytokines in tissues of the retina or optic nerve system over a long period of time.
  • a method for controlling progression of an ocular degenerative disease comprises: (a) providing a composition comprising one or more PKC- ⁇ inhibitors; and (b) administering to a subject an effective amount of the composition at a frequency sufficient to control the progression of the ocular degenerative disease.
  • one or more PKC- ⁇ inhibitors are selected from among those disclosed above.
  • the present invention provides a method for controlling progression of optic nerve degeneration in a subject having hypertensive glaucoma.
  • the method comprises: (a) administering a composition comprising one or more PKC- ⁇ inhibitors to an eye of said subject; and (b) administering to the subject an intraocular-pressure (“IOP") lowering drug, wherein the composition and the IOP lowering drug are administered in effective amounts at a frequency sufficient to control the progression of optic nerve degeneration.
  • IOP intraocular-pressure
  • IOP lowering drugs include prostaglandin analogs (lantanoprost, travoprost, bimatoprost), ⁇ -receptor antagonists (timolol maleate), ⁇ 2 -adrenegic agonists (brionidine, clonidine), carbonic anhydrases (dorzolamide, brinzolamide), cholinomimetics (pilocarpine, carbachol), and inhibitors of acetylcholinesterase such as Echothiophate (phospholine iodide).
  • a composition of the present invention is administered intravitreally.
  • a composition of the present invention is incorporated into an ophthalmic implant system or device, and the implant system or device is surgically implanted in the vitreous cavity of the patient for the sustained or long-term release of the active ingredient or ingredients.
  • a typical implant system or device suitable for use in a method of the present invention comprises a biodegradable matrix with the active ingredient or ingredients impregnated or dispersed therein.
  • Non-limiting examples of ophthalmic implant systems or devices for the sustained-release of an active ingredient are disclosed in U.S. Patents 5,378,475; 5,773,019; 5,902,598; 6,001,386; 6,051,576; and 6,726,918; which are incorporated herein by reference.
  • a composition of the present invention is injected into the vitreous once a month, or once every two, three, four, five, or six months.
  • the composition is implanted in the patient and is replaced at a frequency of, for example, once a year or at a suitable frequency that is determined to be appropriate for controlling the progression of the ocular degenerative disease.
  • a composition or a method of the present invention can be used in conjunction with other therapeutic, adjuvant, or prophylactic agents or methods commonly used to control (a) an increase of intraocular pressure, (b) a loss of neuronal cells of the retinal layers (such as retinal ganglion cells, M ⁇ ller cells, amacrine cells, bipolar cells, horizontal cells, and photoreceptors) or (c) both, thus providing an enhanced overall treatment or enhancing the effects of the other therapeutic, prophylactic, or adjunctive agents or methods used to treat and manage the different ocular neurodegenerative diseases.
  • other therapeutic, adjuvant, or prophylactic agents or methods commonly used to control (a) an increase of intraocular pressure, (b) a loss of neuronal cells of the retinal layers (such as retinal ganglion cells, M ⁇ ller cells, amacrine cells, bipolar cells, horizontal cells, and photoreceptors) or (c) both, thus providing an enhanced overall treatment or enhancing the effects of the other therapeutic, prophylactic, or
  • compositions of the present invention with agents or methods commonly used to control progression of ocular nerve damage allows the use of relatively lower doses of such other agents, or frequency of such other methods, resulting in a lower frequency of potential adverse side effects associated with long-term administration of such therapeutic agents or methods.
  • another indication of the compositions in this invention is to reduce adverse side effects of prior-art drugs or methods used to control optic nerve degeneration, such as the development of cataracts with long-acting anticholinesterase agents including demecarium, echothiophate, and isoflurophate.
  • the present invention provides a method for preparing a composition for the treatment or control of an ocular neurodegenerative condition in a subject, which has an etiology in inflammation.
  • the method comprises combining at least a PKC- ⁇ inhibitor with a pharmactically acceptable carrier.
  • the method may further including adding one or more pharmaceutically acceptable additives for providing certain desirable properties to the composition.
  • a composition of the present invention is prepared to have a form of an emulsion, suspension, or dispersion.
  • the suspension or dispersion is based on an aqueous solution.
  • a composition of the present invention can comprise sterile saline solution.
  • a composition of the present invention can avoid one or more of the side effects of glucocorticoid therapy.
  • Glucocorticoids are among the most potent drugs used for the treatment of allergic and chronic inflammatory diseases.
  • long-term treatment with GCs is often associated with numerous adverse side effects, such as diabetes, osteoporosis, hypertension, glaucoma, or cataract.
  • side effects like other physiological manifestations, are results of aberrant expression of genes responsible for such diseases.
  • Research in the last decade has provided important insights into the molecular basis of GC-mediated actions on the expression of GC-responsive genes. GCs exert most of their genomic effects by binding to the cytoplasmic GC receptor ("GR").
  • GR cytoplasmic GC receptor
  • GCs inhibit the transcription, through the transrepression mechanism, of several cytokines that are relevant in inflammatory diseases, including IL-i ⁇ (interleukin-i ⁇ ), IL-2, IL-3, IL-6, IL-11, TN F- ⁇ (tumor necrosis factor- ⁇ ), GM-CSF (granulocyte-macrophage colony-stimulating factor), and chemokines that attract inflammatory cells to the site of inflammation, including IL-8, RANTES, MCP-1 (monocyte chemotactic protein-1), MCP-3, MCP-4, MIP-i ⁇ (macrophage-inflammatory protein-i ⁇ ), and eotaxin.
  • IL-8 interleukin-i ⁇
  • MCP-1 monoocyte chemotactic protein-1
  • MCP-3 macrophage-inflammatory protein-i ⁇
  • eotaxin eotaxin.
  • IKB kinases which are proteins having inhibitory effects on the NF- ⁇ B pro-inflammatory transcription factors.
  • proinflammatory transcription factors regulate the expression of genes that code for many inflammatory proteins, such as cytokines, inflammatory enzymes, adhesion molecules, and inflammatory receptors.
  • the present invention provides pharmaceutical compositions for the treatment, reduction, alleviation, or amelioration of a pathological condition having an etiology in inflammation, which compositions avoid generation of one or more adverse side effects of GCs.
  • an adverse side effect of GCs is selected from the group consisting of glaucoma, cataract, hypertension, hyperglycemia, hyperlipidemia (increased levels of triglycerides), and hypercholesterolemia (increased levels of cholesterol).
  • a level of said at least an adverse side effect is determined at about one day after said compounds or compositions are first administered to, and are present in, said subject.
  • a level of said at least an adverse side effect is determined about 30 days after said compounds or compositions are first administered to, and are present in, said subject.
  • a level of said at least an adverse side effect is determined about 2, 3, 4, 5, or 6 months after said compounds or compositions are first administered to, and are present in, said subject.
  • said at least a prior-art glucocorticoid used to treat or reduce the same condition or disorder is administered to said subject at a dose and a frequency sufficient to produce the same beneficial effect on said condition or disorder as a compound or composition of the present invention after about the same elapsed time.
  • said at least a prior-art glucocorticoid is selected from the group consisting of 21-acetoxypregnenolone, alclometasone, algestone, amcinonide, beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol, clobetasone, clocortolone, cloprednol, corticosterone, cortisone, cortivazol, deflazacort, desonide, desoximetasone, dexamethasone, diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort, flucloronide, flumethasone, flunisolide, fluocinolone acetonide, fluocinonide, fluocortin butyl, fluocortolone, fluorometholone, fluperolone acetate, flupredn
  • said at least a prior-art glucocorticoid is selected from the group consisting of dexamethasone, prednisone, prednisolone, methylprednisolone, medrysone, triamcinolone, loteprednol etabonate, physiologically acceptable salts thereof, combinations thereof, and mixtures thereof.
  • said at least a prior-art glucocorticoid is acceptable for ophthalmic uses.
  • PKC- ⁇ inhibitors are not expected to generate side effects that have been seen with glucocorticoid therapy. However, such effects may still be assessed by a test disclosed below.
  • One of the most frequent undesirable actions of a glucocorticoid therapy is steroid diabetes. The reason for this is the stimulation of gluconeogenesis in the liver by the induction of the transcription of hepatic enzymes involved in gluconeogenesis and metabolism of free amino acids that are produced from the degradation of proteins (catabolic action of glucocorticoids).
  • a key enzyme of the catabolic metabolism in the liver is the tyrosine aminotransferase ("TAT"). The activity of this enzyme can be determined photometrically from cell cultures of treated rat hepatoma cells.
  • the gluconeogenesis by a glucocorticoid can be compared to that of a PKC- ⁇ inhibitor by measuring the activity of this enzyme.
  • the cells are treated for 24 hours with the test substance (a PKC- ⁇ inhibitor or a glucocorticoid), and then the TAT activity is measured.
  • the TAT activities for the selected PKC- ⁇ inhibitor and glucocorticoid are then compared.
  • Other hepatic enzymes can be used in place of TAT, such as phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, or fructose-2,6- biphosphatase.
  • the levels of blood glucose in an animal model may be measured directly and compared for individual subjects that are treated with a glucocorticoid for a selected condition and those that are treated with a PKC- ⁇ inhibitor for the same condition.
  • IOP Another undesirable result of glucocorticoid therapy is increased IOP in the subject.
  • IOP of subjects treated with a glucocorticoid or a PKC- ⁇ inhibitor for a condition may be measured directly and compared.
  • Benefits of a composition of the present invention for neuroprotection can be determined, judged, estimated, or inferred by conducting assays and measurements, for example, to determine: (1) the protection of nerve cells from glutamate induced toxicity; and/or (2) the neural protection in a nerve crush model of mechanical injury.
  • assays and measurements are disclosed in US Patent 6,194,415; which is incorporated herein by reference.
  • compositions Comprising PKC-delta Modulators and Methods for Ocular Neuroprotection
  • Gly val Ala Gly Glu Asp Met Gin Asp Asn Ser Gly Thr Tyr Gly Lys 325 330 335 lie Trp Glu Gly Ser ser Lys Cys Asn lie Asn Asn phe lie Phe His 340 345 350
  • Lys Gly Arg Gly Glu Tyr Phe Ala lie Lys Ala Leu Lys Lys Asp Val 370 375 380
  • Val Leu lie Asp Asp Asp Val Glu Cys Thr Met val Glu Lys Arg Val 385 390 395 400 Leu Thr Leu Ala Ala Glu Asn Pro Phe Leu Thr His Leu lie Cys Thr 405 410 415
  • Glu Asn lie Phe Gly Glu Ser Arg Ala Ser Thr Phe Cys Gly Thr Pro 500 505 510
  • Val Asp Trp Trp ser Phe Gly val Leu Leu Tyr Glu Met Leu lie Gly 530 535 540

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des compositions pour traiter ou lutter contre une dégénérescence d'au moins un composant du système nerveux optique humain, qui comprend un modulateur de la protéine kinase Gdelta (« PKC-delta »). Un tel modulateur PKC-delta peut être un composé qui empêche, réduit, ou interfère sensiblement avec une activité d'une cascade de signalisation cellulaire mettant en jeu PKC-delta ou une activation de PKC-delta. Les compositions peuvent également comprendre un médicament anti-inflammatoire. De telles compositions peuvent être administrées pour fournir une neuroprotection à un patient souffrant d'une maladie oculaire, telle qu'un glaucome, une dégénérescence maculaire liée à l'âge (AMD), une rétinopathie diabétique (DR), ou une rétinite pigmentaire.
PCT/US2009/034466 2008-02-29 2009-02-19 Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire Ceased WO2009111169A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3258408P 2008-02-29 2008-02-29
US61/032,584 2008-02-29

Publications (2)

Publication Number Publication Date
WO2009111169A2 true WO2009111169A2 (fr) 2009-09-11
WO2009111169A3 WO2009111169A3 (fr) 2010-02-25

Family

ID=40762329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/034466 Ceased WO2009111169A2 (fr) 2008-02-29 2009-02-19 Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire

Country Status (1)

Country Link
WO (1) WO2009111169A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795640B2 (en) 2011-12-22 2014-08-05 Mary Kay Inc. Lip formulation
WO2017121766A1 (fr) 2016-01-12 2017-07-20 Kaleyde Pharmaceuticals Ag Formulations pharmaceutiques et leur utilisation pour le traitement de la rétinite pigmentaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048582A1 (en) * 2000-07-18 2002-04-25 King George L. Methods of modulating angiogenesis
EP2194124A1 (fr) * 2005-09-19 2010-06-09 Kai Pharmaceuticals, Inc. Peptide modulateurs de la protéine kinase c de l'angiogenèse
US20080153903A1 (en) * 2006-12-22 2008-06-26 Alcon Manufacturing, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795640B2 (en) 2011-12-22 2014-08-05 Mary Kay Inc. Lip formulation
WO2017121766A1 (fr) 2016-01-12 2017-07-20 Kaleyde Pharmaceuticals Ag Formulations pharmaceutiques et leur utilisation pour le traitement de la rétinite pigmentaire

Also Published As

Publication number Publication date
WO2009111169A3 (fr) 2010-02-25

Similar Documents

Publication Publication Date Title
Zhang et al. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
KR101720562B1 (ko) Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
RU2722643C2 (ru) Способ лечения болезней глаз
RU2718850C2 (ru) Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
Zhou et al. Pegaptanib for the treatment of age-related macular degeneration
UA125432C2 (uk) Оптимізовані варіанти анти-vegf антитіл
US20110189174A1 (en) Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
JP2015157862A (ja) 眼疾患を処置するための補体経路の阻害剤の使用
KR20200113290A (ko) 혈관 형성의 억제를 필요로 하는 대상체에서 혈관 형성을 억제하는 방법
CN108697793A (zh) 治疗眼睛疾病的方法
Waisbourd et al. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration
Kunimoto et al. Evaluation of abicipar pegol (an anti-VEGF DARPin therapeutic) in patients with neovascular age-related macular degeneration: studies in Japan and the United States
Kanda et al. (Pro) renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy
KR20180105235A (ko) 질병 치료를 위한 항체-약물 상승작용 기술
TW200815416A (en) Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases
JP2023099171A (ja) 緑内障を治療するためのＷｎｔ５ａの調節
WO2009089399A2 (fr) Compositions comprenant des antagonistes du récepteur ou du co-récepteur de type toll et procédés de neuroprotection oculaire
WO2009023411A1 (fr) Compositions et procédés destinés à traiter ou contrôler des maladies ophtalmiques du segment antérieur et postérieur
EP2671589A1 (fr) Agent médicinal pour la prévention ou le traitement de maladies associées à une néovascularisation intraoculaire et/ou une hyperperméabilité vasculaire intraoculaire
WO2009111169A2 (fr) Compositions comprenant des modulateurs pkc-delta et procédés pour une neuroprotection oculaire
JP7356994B2 (ja) 網膜炎症および神経変性を処置するためのｉｌ－３４の使用
US20130028889A1 (en) Dosing regimens for treating and preventing ocular disorders using c-raf antisense
US20090291073A1 (en) Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
JP2025111432A (ja) 色素上皮由来因子（ｐｅｄｆ）を使用する疾患の処置のための方法
US10011837B2 (en) SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09718261

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09718261

Country of ref document: EP

Kind code of ref document: A2